Literature DB >> 22876773

Hemokinin-1 as an adjuvant molecule enhancing humoral and memory responses to HBsAg DNA vaccination.

Xuan Chen1, Wang Zhang, Wenqing Gao, Qiang Zou, Congcong Feng, Hu Liu, Chenliang Zhou, Yu Zhang, Bin Wang.   

Abstract

Incorporation of molecular adjuvants into DNA vaccines is often used to improve the induction of immune responses, but few approaches aim to specifically activate B cells for an enhanced humoral response only. Hemokinin-1 (HK-1) is a factor that activates B cells for proliferation, survival, differentiation into plasma cells, and Ab production. Therefore, we investigated if it may be used as a molecular adjuvant for DNA vaccines to elicit strong humoral and memory responses. The HK-1 coding sequence was sub-cloned as single or triple copies in-frame downstream of S2 HBsAg in the proVAX/S2 construct. Compared to mice immunized with proVAX/S2 or proVAX/S2-HK-1, proVAX/S2-3HK-1 induced a higher level of IgG production, a higher percentage of differentiated antibody-secreting plasma cells, and a higher level of T-cell proliferation. Furthermore, a higher proportion of B cells had the B220(+)CD27(+) phenotype in these groups, and specific antigen re-challenge induced a higher level of total IgG production 60 d after the last immunization, suggesting that the use of HK-1 as an adjuvant promoted immunological memory. Taken together, these results suggest that using HK-1 as an adjuvant molecule could enhance the immunogenicity of HBsAg DNA vaccines, and result in stronger humoral and memory responses. Therefore, HK-1 may lead to the development of a novel humoral-biased molecular adjuvant for an HBsAg DNA vaccine against hepatitis B infection.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22876773     DOI: 10.1089/vim.2012.0015

Source DB:  PubMed          Journal:  Viral Immunol        ISSN: 0882-8245            Impact factor:   2.257


  2 in total

1.  Design of a heterosubtypic epitope-based peptide vaccine fused with hemokinin-1 against influenza viruses.

Authors:  Shahla Shahsavandi; Mohammad Majid Ebrahimi; Kaveh Sadeghi; Homayoon Mahravani
Journal:  Virol Sin       Date:  2015-04-15       Impact factor: 4.327

Review 2.  Prophylactic vaccinations in chronic kidney disease: Current status.

Authors:  Alicja E Grzegorzewska
Journal:  Hum Vaccin Immunother       Date:  2015-04-27       Impact factor: 3.452

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.